Sign in
Stories
Breakthrough Canine Cancer Treatment Approved
Share
Adagene Advances Clinical Collaboration
Advancements in Antibodies to Protect Im...
Advancements in Cancer Treatment and Mar...
AB-2100 Phase 1/2 Trial Initiated
AI-Powered Antigen Research Partnership
BioNTech's mRNA Cancer Vaccine Progress
Overview
API
ELIAS Animal Health secures USDA nod for innovative cancer immunotherapy to combat osteosarcoma in canines. Their ELIAS Cancer Immunotherapy integrates personalized cancer cell vaccines with adoptive T-cell therapy, exhibiting encouraging outcomes in canine trials. The company aims to enhance therapy accessibility and efficacy through apheresis center expansions and immune checkpoint inhibitor investigations.
Ask a question
How might the success of ELIAS's cancer immunotherapy in dogs pave the way for similar treatments in other animals or even humans?
In what ways could the integration of immune checkpoint inhibitors with ELIAS's cancer immunotherapy impact the future of cancer treatment?
What challenges could ELIAS face in scaling up production and distribution of their innovative therapy for widespread use?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage
aaha.